Pharmacologic Prevention of Stuttering Priapism in Adolescent Sickle Cell Disease
A fifteen-year-old boy with sickle cell disease and increasingly frequent stuttering priapism has asked directly whether treatment could affect how tall he still grows, which every option on a case-series-only evidence base has to answer honestly, not just the hormonal ones.
Malachi B., a fifteen-year-old boy with homozygous sickle cell disease (HbSS), has had eleven episodes of painful nighttime erection over the past four months, each resolving on its own within ninety minutes to two hours without an emergency visit — stuttering priapism, distinct from the single prolonged ischemic episode that would be a true urologic emergency. He has been on maximally tolerated hydroxyurea for sickle cell disease management for three years, is being actively recruited by two high school basketball programs, and has asked his hematologist directly, without his parents in the room, whether any of the medications being discussed could affect how much taller he still grows — he is mid-puberty by Tanner staging and has not yet had his adolescent growth spurt.
The episodes are frequent enough now to warrant prevention beyond simply riding out each one, but the entire preventive literature for stuttering priapism rests on case series and small case reports, not randomized trials — a reality that shapes every option on the table more than the mechanism does. Hydroxyurea itself, already part of his regimen, has documented case-series evidence of reducing priapism frequency, including Anele and colleagues' 2014 report of erectile-function recovery after dose escalation, through a proposed nitric-oxide-donor effect distinct from its usual role in reducing sickling. Alpha-adrenergic agonists — the class-defining case series is Virag and colleagues' work with etilefrine, with oral pseudoephedrine used as the same-mechanism agent more available in the United States — and hormonal options including GnRH agonists, antiandrogens, and 5-alpha-reductase inhibitors, all have case-series-level support for reducing episode frequency — but the hormonal options work specifically by suppressing the androgen exposure that, in a mid-pubertal boy who has asked directly about his own growth, is not a side detail anyone can treat as incidental. Left unaddressed, frequent stuttering episodes are also the clearest known risk factor for a future prolonged ischemic episode, the kind that carries a real, fast-acting threat to erectile tissue — the actual stake underneath a symptom his classmates would probably just call inconvenient.
Eleven episodes in four months, and a question about how tall he'll get
Before adding anything new, I want to confirm he's actually at his maximum tolerated hydroxyurea dose — Anele and colleagues' case report describes both prevention of stuttering episodes and recovery of erectile function after escalating the dose further, through a proposed nitric oxide donor effect that's separate from its usual anti-sickling mechanism. If there's room to titrate up before we reach for a second drug, that's the option with no growth or hormonal cost at all, which matters given what he's already told us he cares about.
Optimizing hydroxyurea is reasonable as a first step, but I wouldn't wait on it alone if he's already near his ceiling — eleven episodes in four months is frequent enough that I'd add bedtime oral pseudoephedrine now, in parallel. It's an alpha-agonist working directly on the vascular mechanism, case-series-supported for exactly this indication, and it doesn't touch his androgen axis at all, which keeps every hormonal option in reserve rather than reaching for one prematurely.
I agree completely that anything hormonal should stay in reserve here, and not just as a general caution — he asked directly, on his own, whether these drugs could affect his height, which tells me this isn't an abstract growth-chart concern to him.
If we do reach the point where hydroxyurea and pseudoephedrine haven't controlled this, I want it said plainly to him, not just documented in the chart, that a GnRH agonist or antiandrogen would suppress the same androgen surge driving the growth spurt he's waiting for — that's a real conversation to have with him directly, at his age, before it becomes the next step rather than after.
Malachi's hydroxyurea dose was confirmed at maximum tolerated, and bedtime pseudoephedrine was added the same visit, with hormonal options held in reserve and explicitly discussed with him directly, not just with his parents.
Not settled: how many more breakthrough episodes on this combination should trigger the hormonal conversation the endocrinologist wants to have with him personally before it happens, versus waiting for a clear treatment failure. The hematologist would give the current combination a full three months before revisiting; the endocrinologist would rather have that harder conversation early and optionally, while there's no time pressure, than wait until frequency alone is forcing the decision.